Evidence map›Paper›PMID 35965451›Full record

ArticlemAbs

NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells.

Hema Preethi Subas Satish, Kathleen Zeglinski, Rachel T Uren, Stephen L Nutt, Matthew E Ritchie, Quentin Gouil, Ruth M Kluck

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Fluorescence-activated droplet sequencing (FAD-seq) directly provides sequences of screening hits in antibody discovery.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hema Preethi Subas SatishBlood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research , Melbourne, Australia.ORCID 0000-0003-0626-8764
Kathleen ZeglinskiDepartment of Medical Biology, University of Melbourne, Melbourne, Australia.ORCID 0000-0003-0608-229X
Rachel T UrenBlood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research , Melbourne, Australia.ORCID 0000-0001-7456-478X
Stephen L NuttDepartment of Medical Biology, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-0020-6637
Matthew E RitchieDepartment of Medical Biology, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-7383-0609
Quentin GouilDepartment of Medical Biology, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-5142-7886
Ruth M KluckBlood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research , Melbourne, Australia.ORCID 0000-0002-7101-1925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite their common use in research, monoclonal antibodies are currently not systematically sequenced. This can lead to issues with reproducibility and the occasional loss of antibodies with loss of cell lines. Hybridoma cell lines have been the primary means of generating monoclonal antibodies from immunized animals, including mice, rats, rabbits, and alpacas. Excluding therapeutic antibodies, few hybridoma-derived antibody sequences are known. Sanger sequencing has been "the gold standard" for antibody gene sequencing, but this method relies on the availability of species-specific degenerate primer sets for amplification of light and heavy antibody genes and it requires lengthy and expensive cDNA preparation. Here, we leveraged recent improvements in long-read Oxford Nanopore Technologies (ONT) sequencing to develop Nanopore Antibody sequencing (NAb-seq): a three-day, species-independent, and cost-effective workflow to characterize paired full-length immunoglobulin light- and heavy-chain genes from hybridoma cell lines. When compared to Sanger sequencing of two hybridoma cell lines, long-read ONT sequencing was highly accurate, reliable, and amenable to high throughput. We further show that the method is applicable to single cells, allowing efficient antibody discovery in rare populations such as memory B cells. In summary, NAb-seq promises to accelerate identification and validation of hybridoma antibodies as well as antibodies from single B cells used in research, diagnostics, and therapeutics.

Indexed as

Antibodies, MonoclonalHigh-Throughput Nucleotide SequencingAnimalsCell LineCost-Benefit AnalysisHybridomasMiceRabbitsRatsReproducibility of ResultsAntibodies, MonoclonalAntibody sequencingB cellhybridomalong-readnanopore sequencingrat B cell cloningsingle cellworkflow

Identifiers

PMID35965451
PMCPMC9377246

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.